What is HC Wainwright’s Forecast for MNPR FY2026 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for Monopar Therapeutics in a report issued on Thursday, November 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($2.80) per share for the year, up from their prior estimate of ($3.07). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2026 earnings at ($0.99) EPS, FY2027 earnings at ($4.32) EPS, FY2028 earnings at ($0.13) EPS, FY2029 earnings at $5.13 EPS and FY2030 earnings at $7.93 EPS.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.72) earnings per share for the quarter, meeting the consensus estimate of ($0.72).

A number of other analysts have also recently weighed in on the stock. BTIG Research reiterated a “buy” rating on shares of Monopar Therapeutics in a research note on Thursday, November 12th. Cantor Fitzgerald raised shares of Monopar Therapeutics from a “neutral” rating to an “overweight” rating and set a $119.00 price objective on the stock in a research report on Thursday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Finally, UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Monopar Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $123.12.

Get Our Latest Stock Report on MNPR

Monopar Therapeutics Stock Down 1.3%

Shares of Monopar Therapeutics stock opened at $71.06 on Monday. The firm’s fifty day simple moving average is $80.82 and its 200-day simple moving average is $77.45. Monopar Therapeutics has a 12 month low of $50.07 and a 12 month high of $124.82.

Hedge Funds Weigh In On Monopar Therapeutics

A number of large investors have recently bought and sold shares of MNPR. State Street Corp boosted its holdings in shares of Monopar Therapeutics by 24.1% in the third quarter. State Street Corp now owns 229,771 shares of the company’s stock valued at $18,306,000 after acquiring an additional 44,669 shares in the last quarter. Siren L.L.C. increased its stake in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the period. ADAR1 Capital Management LLC raised its holdings in Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Monopar Therapeutics during the second quarter worth about $7,124,000. Finally, Goldman Sachs Group Inc. raised its holdings in Monopar Therapeutics by 443.8% during the third quarter. Goldman Sachs Group Inc. now owns 87,877 shares of the company’s stock worth $7,001,000 after purchasing an additional 71,716 shares in the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Insider Buying and Selling

In other news, Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the sale, the director owned 23,751 shares in the company, valued at $2,654,649.27. This represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Starr sold 8,400 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $78.50, for a total value of $659,400.00. Following the sale, the director owned 5,173 shares of the company’s stock, valued at $406,080.50. This trade represents a 61.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 51,920 shares of company stock worth $4,527,913. 9.70% of the stock is currently owned by company insiders.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

Recommended Stories

Earnings History and Estimates for Monopar Therapeutics (NASDAQ:MNPR)

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.